LCMV gp33-41 is the H-2Db restricted epitope derived from the lymphocytic choreomeningitis virus (LCMV) glycoprotein gp 33; residues 33 to 41.
CAT No: R1478
CAS No:151705-84-9
Synonyms/Alias:LCMV gp33-41;151705-84-9;BGA70584;(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylsulfanylbutanoic acid;G13111;
LCMV gp33-41 is a synthetic peptide corresponding to residues 33 to 41 of the glycoprotein (GP) from lymphocytic choriomeningitis virus (LCMV). As a well-characterized immunodominant epitope, it is widely recognized for its pivotal role in T cell immunology and virology research. The sequence is frequently utilized as a model antigen in studies exploring cytotoxic T lymphocyte (CTL) responses, antigen processing, and epitope recognition. Its defined nature and high relevance to murine models have made it an essential tool for dissecting the mechanisms of antiviral immunity, immunodominance hierarchies, and T cell receptor (TCR) specificity.
Antigen-specific T cell activation: The LCMV gp33-41 peptide is extensively used to stimulate CD8+ T cells in both in vitro and in vivo settings, particularly within murine models expressing the H-2Db major histocompatibility complex (MHC) class I molecule. By providing a defined epitope, it enables researchers to precisely monitor and quantify antigen-specific CTL responses, facilitating the analysis of T cell activation, proliferation, and effector function. This application is foundational for dissecting the cellular immune response to viral infection and for evaluating the specificity and magnitude of T cell-mediated immunity.
Immunological assay development: The peptide serves as a critical reagent in the development and validation of immunological assays such as ELISPOT, intracellular cytokine staining, and tetramer staining. Its use allows for the standardized detection of gp33-41-specific T cells, supporting the assessment of immune responses in experimental infection models or immunization studies. The reproducibility and specificity of responses elicited by this epitope make it an essential positive control in the optimization and benchmarking of T cell assays.
T cell receptor (TCR) specificity studies: Researchers employ LCMV gp33-41 to probe the molecular basis of TCR recognition, cross-reactivity, and affinity maturation. By presenting this peptide to T cells with known or engineered TCRs, investigators can elucidate the structural and kinetic determinants of peptide-MHC recognition. Such studies are instrumental in advancing the understanding of TCR repertoire selection, antigen sensitivity, and the mechanisms underlying immunodominance during viral infection.
Vaccine and immunotherapy model systems: The defined immunogenicity of the gp33-41 epitope enables its incorporation into model vaccine platforms and adoptive cell transfer protocols. In these contexts, the peptide is used to evaluate the efficacy of novel vaccine adjuvants, delivery systems, or engineered T cell therapies. Its role as a benchmark antigen supports the preclinical assessment of immune interventions, offering a controlled system for measuring the induction and recall of antigen-specific T cell responses.
Antigen processing and presentation research: The gp33-41 peptide is also valuable for dissecting the pathways of antigen processing and MHC class I presentation. By comparing the immune response to exogenously loaded peptide versus endogenously processed viral proteins, scientists can investigate the efficiency and fidelity of antigen presentation machinery. These studies provide insights into the molecular mechanisms that govern immune surveillance, epitope selection, and viral immune evasion strategies.
Collectively, the LCMV gp33-41 peptide is an indispensable tool in immunology and virology research, underpinning a wide range of experimental approaches aimed at unraveling the complexities of antigen recognition, T cell function, and antiviral defense mechanisms. Its versatility and well-established relevance continue to drive advances in basic and translational studies of immune responses to viral infection.
2. Emu oil in combination with other active ingredients for treating skin imperfections
3. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment
4. SERS spectrum of the peptide thymosin‐β4 obtained with Ag nanorod substrate
5. Cationic cell-penetrating peptides are potent furin inhibitors
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More